Literature DB >> 10510161

Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers.

I Ragueneau1, J M Poirier, N Radembino, A B Sao, C Funck-Brentano, P Jaillon.   

Abstract

AIMS: The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of macrogol 4000 (a laxative polymer) in 18 healthy volunteers.
METHODS: This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with macrogol 4000, 20 g day-1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed.
RESULTS: Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P<0.05). Digoxin tmax and t1/2,z were not significantly altered. Heart rate and PR interval did not differ during the two therapeutic sequences, digoxin alone and digoxin in combination.
CONCLUSIONS: Macrogol 4000 coadministration interacts with single-dose digoxin pharmacokinetics. This is most likely due to a reduction of the intestinal absorption of digoxin. However, there was no consequence of this interaction on heart rate and AV conduction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510161      PMCID: PMC2014333          DOI: 10.1046/j.1365-2125.1999.00025.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Improved sensitivity of digoxin assay by modification of the EMIT 2000 method.

Authors:  N Radembino; J M Poirier; I Ragueneau; P Jaillon
Journal:  Ther Drug Monit       Date:  1999-04       Impact factor: 3.681

2.  Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.

Authors:  D E Martin; D Tompson; S C Boike; D Tenero; B Ilson; D Citerone; D K Jorkasky
Journal:  Br J Clin Pharmacol       Date:  1997-06       Impact factor: 4.335

3.  Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers.

Authors:  R C Dockens; D S Greene; R H Barbhaiya
Journal:  J Clin Pharmacol       Date:  1996-02       Impact factor: 3.126

Review 4.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 5.  Digitalis (third of four parts).

Authors:  T W Smith; E Haber
Journal:  N Engl J Med       Date:  1973-11-15       Impact factor: 91.245

6.  Drug interactions with digoxin.

Authors:  D D Brown; R Spector; R P Juhl
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

7.  [Low-dose polyethylene glycol 4000: digestive effects. Randomized double-blind study in healthy subjects].

Authors:  H Hudziak; J P Bronowicki; P Franck; C Dubos-Berogin; M A Bigard
Journal:  Gastroenterol Clin Biol       Date:  1996

8.  Lack of effect of mizolastine on the safety and pharmacokinetics of digoxin administered orally in repeated doses to healthy volunteers.

Authors:  S Chaufour; F Le Coz; T Denolle; C Dubruc; I Cimarosti; C Deschamps; N Ulliac; B Delhotal-Landes; P Rosenzweig
Journal:  Int J Clin Pharmacol Ther       Date:  1998-05       Impact factor: 1.366

9.  Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients.

Authors:  L B Mitchell; K R Jutzy; S J Lewis; J S Schroeder; J W Mason
Journal:  Am Heart J       Date:  1982-01       Impact factor: 4.749

10.  Pharmacokinetics of amoxicillin coadministered with a saline-polyethylene glycol solution in healthy volunteers.

Authors:  C Padoin; M Tod; N Brion; K Louchahi; V Le Gros; O Petitjean
Journal:  Biopharm Drug Dispos       Date:  1995-04       Impact factor: 1.627

View more
  6 in total

Review 1.  Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs.

Authors:  Mei-Ling Chen; Nakissa Sadrieh; Lawrence Yu
Journal:  AAPS J       Date:  2013-07-19       Impact factor: 4.009

2.  Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.

Authors:  Emmanuelle Comets; Céline Verstuyft; Marc Lavielle; Patrice Jaillon; Laurent Becquemont; France Mentré
Journal:  Eur J Clin Pharmacol       Date:  2007-03-13       Impact factor: 2.953

3.  Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.

Authors:  Yuansheng Zhao; Zhe-Yi Hu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Digoxin pharmacokinetics and MDR1 genetic polymorphisms.

Authors:  Céline Verstuyft; Mathias Schwab; Elke Schaeffeler; Reinhold Kerb; Ulrich Brinkmann; Patrice Jaillon; Christian Funck-Brentano; Laurent Becquemont
Journal:  Eur J Clin Pharmacol       Date:  2003-03-01       Impact factor: 2.953

5.  Assessment of Clinical Practices for Crushing Medication in Geriatric Units.

Authors:  M Fodil; D Nghiem; M Colas; S Bourry; A-S Poisson-Salomon; H Rezigue; C Trivalle
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

6.  Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2018-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.